Talis Biomedical Corporation TLIS
2.84
0.00
0.00%
as of 1 Apr
- Market cap
- $46.3M
- P/E
- 0.0×
Follow TLIS
Growth Flags
show if company had growth for consecutive years
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | |
|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 5.39 | 5.39 | 5.39 | 11.09 | 2.75 | 6.85 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | (1.61) | (1.61) | (1.61) | (2.23) | (0.98) | (1.29) |
P/B ratio |
— | 0.00 | 0.00 | 0.00 | 0.39 | 0.10 | 0.21 |
Price to Tangible BV |
— | 0.00 | 0.00 | 0.00 | 0.39 | 0.10 | 0.21 |
EV/Sales |
— | (10.44) | (10.44) | (10.44) | (17.29) | (24.31) | (29.11) |
EV/EBITDA |
— | 1.26 | 1.26 | 1.26 | 0.74 | 1.10 | 0.94 |
EV/Operating CF |
— | 1.31 | 1.31 | 1.31 | 0.83 | 1.17 | 1.17 |
EV/FCF |
— | 1.20 | 1.20 | 1.20 | 0.81 | 1.15 | 1.16 |
Quick Ratio |
— | 2.64 | 5.80 | 10.83 | 12.18 | 10.30 | 8.75 |
Current Ratio |
— | 2.77 | 5.97 | 11.77 | 12.36 | 10.52 | 8.86 |
Net Debt/EBITDA |
— | 0.33 | 0.83 | 1.91 | 1.22 | 1.22 | 1.16 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.42 | 0.21 | 0.10 | 0.04 | 0.02 | 0.02 |
Operating CF/Net income |
— | 0.98 | (0.92) | 0.95 | 0.89 | 0.89 | 0.86 |
Capex/Depreciation |
— | 0.00 | (0.80) | (10.75) | (1.82) | (0.18) | (0.63) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 58.34% | (72.14%) | 140.51% | (306.27%) | (62.66%) | (63.32%) | |
| — | (375.06%) | 142.18% | (81.32%) | (82.73%) | (51.95%) | (46.98%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | (8,371.86%) | 0.00% | 0.00% |
Return on Tangible Assets |
— | (274.29%) | 122.11% | (50.12%) | (84.40%) | (91.20%) | (86.19%) |
Average Days of Receivables |
— | 304.98 | 165.75 | 15.72 | 8.15 | 23.36 | 8.55 |
Research and Development Expense of Revenue |
— | 769.37% | 598.74% | 813.85% | 1,923.48% | 1,471.97% | 1,906.94% |
Selling, General and Administrative Expense of Revenue |
— | 200.21% | 172.59% | 119.79% | 517.73% | 846.40% | 1,322.12% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 24.26% | 33.67% | 112.38% | 111.55% | 203.89% |
Graham Net Nets |
— | (2.01) | (2.01) | (2.01) | 2.25 | 6.86 | 3.57 |
Graham Number |
— | 0.00 | 0.00 | 3,336.49 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (154.52%) | (154.52%) | (154.52%) | (211.09%) | (864.88%) | (425.06%) |
Free Cash Flow Yield |
— | (161.50%) | (161.50%) | (161.50%) | (191.71%) | (768.92%) | (367.67%) |
Revenue per Share |
— | 0.67 | 77.52 | 77.36 | 5.42 | 2.67 | 1.17 |
Operating CF per Share |
— | (5.89) | (474.19) | (615.45) | (113.42) | (55.62) | (29.29) |
Capex per Share |
— | 0.00 | (11.27) | (58.00) | (1.90) | (0.90) | (0.27) |
Free Cash Flow per Share |
— | (5.89) | (485.46) | (673.44) | (115.31) | (56.52) | (29.56) |
Cash per Share |
— | 1.94 | 421.13 | 1,224.42 | 153.89 | 72.31 | 42.22 |
Shareholders Equity per Share |
— | 2.16 | (412.09) | (767.83) | 154.84 | 70.39 | 38.03 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 2.16 | (412.09) | (767.83) | 154.84 | 70.39 | 38.03 |
Free Cash Flow |
— | (20.94) | (24.90) | (95.22) | (174.25) | (101.75) | (53.73) |
Working Capital |
— | 5.97 | 20.07 | 172.69 | 217.01 | 120.61 | 68.91 |
Capital Expenditures |
— | (0.53) | (0.58) | (8.20) | (2.87) | (1.61) | (0.49) |
Net Current Asset Value |
— | 5.65 | (22.77) | (118.25) | 204.26 | 90.73 | 52.13 |
EV/EBIT |
— | 1.25 | 1.25 | 1.25 | 0.74 | 1.02 | 0.93 |
Capex to Sales |
— | 0.00 | 0.15 | 0.75 | 0.35 | 0.34 | 0.23 |
Net Profit Margin |
— | (892.76%) | 663.36% | (833.15%) | (2,343.90%) | (2,348.55%) | (2,905.67%) |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||
Depreciation/Fixed assets |
— | 0.36 | 0.47 | 0.08 | 0.15 | 2.67 | 0.25 |
Cash ROIC |
— | (155.97%) | (5,573.49%) | (148.91%) | (38.99%) | (40.26%) | (38.58%) |
Accounts Receivable Turnover |
— | 1.26 | 2.09 | 9.61 | 25.06 | 19.60 | 11.92 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.52 | 1.89 | 0.02 |
Inventory Turnover |
— | — | — | — | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 713.29 | 163.90 | 11,920.37 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 1.90 | 1.90 | 1.14 | 0.33 | 0.25 | 0.18 |
Average Payables |
— | 1.54 | 1.54 | 3.24 | 5.01 | 4.45 | 2.55 |
Average Assets |
— | 5.69 | 18.56 | 112.07 | 232.12 | 217.56 | 131.98 |
Average Common Equity |
— | (36.57) | (36.57) | (64.86) | 62.70 | 180.36 | 97.92 |
Columns are period end dates